SAVA Cassava Sciences

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference, being held in New York.

Rick Barry, Cassava’s Executive Chairman, will join in a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright.

Institutional investors who are registered for this conference may log into to request a meeting with Cassava Sciences, pending availability.

Event details follow:

Date:Monday, September 9th
Time:3:00pm to 3:30 Eastern Time
Webcast:
  

A live webcast will be available on the “Investors” page of Cassava Sciences’ website, . An archived replay will be available for 90 days following the event.

About Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.

For More Information Contact:

Eric Schoen, Chief Financial Officer

(512) 501-2450 or 



EN
03/09/2024

Underlying

SAVACassava Sciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cassava Sciences

 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Resolves SEC Investigation

Cassava Sciences Resolves SEC Investigation AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 Phase 2b clinical trial of simufilam and related matters. Two former senior employees of the Company als...

September 26, 2024 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Announces Completion of an Interim Safety Review of O...

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification.Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program. AUSTIN, Texas, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today ...

September 24, 2024 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Names Rick Barry as Chief Executive Officer

Cassava Sciences Names Rick Barry as Chief Executive Officer Claude Nicaise, M.D. appointed Chairman of the Board AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it has concluded its search for a Chief Executive Officer and that its Board of Directors has named Richard (Rick) Barry as CEO. Mr. Barry has served as a director of Cassava since June 2021. On July 17 of this year, the Board appointed him Executive Chairman of the Board and the Company’s principal executive officer...

September 9, 2024 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences to Present at the H.C. Wainwright Global Investment C...

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference, being held in New York. Rick Barry, Cassava’s Executive Chairman, will join in a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright. Institutional investors who are regi...

September 3, 2024 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Reports Q2 2024 Financial Results and Operational Up...

Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates $207.3 Million in Cash and Cash Equivalents at June 30, 2024.Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for Resolution.Conference Webcast Scheduled for Today at 8:30AM ET. AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) --  Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on a novel treatment for Alzheimer’s disease, today reported financial results for the second quarter ended June 30, 2024. Net income was $6.2 million...

August 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch